**JOURNAL CLUB-DASIGLUCAGON**

**INDICATION:**

* Anti-hypoglycemic agent

For the treatment of severe hypoglycemia in pediatric above 6 years and adult patients with diabetes.

* Approved by FDA on March 2021.

**CHEMICAL DESCRIPTION:**

* Molecular formula: C152H222N38O50
* Molecular weight: 3382 g/mol

**DOSAGE AND ADMINISTRATION:**

* 0.6 mg/0.6 ml single-dose autoinjector/pre-filled syringe.

**PHARMACOKINETICS:**

* Route of administration-subcutaneous
* Dosage-0.6 mg
* Volume of distribution-47 L to 57 L
* Half-life - 30 minutes
* Metabolism-cleared like native glucagon through proteolytic degradation pathways in blood, liver, and kidney.

**MECHANISM OF ACTION:**

* Glucagon receptor agonist, by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for dasiglucagon to produce an anti-hypoglycemic effect.

**CONTRAINDICATIONS:**

* Pheochromocytoma because of the risk of substantial increase in blood pressure.
* Insulinoma because of the risk of hypoglycemia.

**ADVERSE DRUG REACTIONS:**

* Adults: nausea, vomiting, headache, diarrhea, and injection site pain.
* Pediatrics: nausea, vomiting, headache, and injection site pain.

**DRUG INTERACTIONS:**

* Beta-blockers: Patients taking beta-blockers may have a transient increase in pulse and blood pressure.
* Indomethacin: In patients taking indomethacin, ZEGALOGUE may lose its ability to raise blood glucose or may produce hypoglycemia.
* Warfarin: ZEGALOGUE may increase the anticoagulant effect of warfarin.

**USE IN SPECIFIC POPULATION:**

* PREGNANCY: No data on human study.
* LACTATION: No data on human study.
* PAEDIATRIC: Safety and Efficacy had not been established under 6 years, safe above 6 years.
* GERIATRIC: No dose adjustment required.

**PHARMACOECONOMICS:**

* Available in US in different prices ranging from $10 to $630 (single shot/multiple doses).

THANK YOU